Q4 EPS Estimates for Core Scientific Reduced by Roth Capital

Key Points

• Roth Capital has reduced its Q4 2026 earnings per share estimate for Core Scientific from $0.03 to $0.01, maintaining a "Neutral" rating with a $17.00 price target.
• The consensus estimate for Core Scientific's full-year earnings is now projected at $0.52 per share, with forecasts for FY2027 and FY2028 standing at $0.16 and $0.99 EPS, respectively.
• Core Scientific's stock has experienced significant fluctuations, recording a fifty-two week low of $6.20 and a high of $18.63, with the current trading price at $13.55.

Core Scientific, Inc. (NASDAQ:CORZ - Free Report) - Investment analysts at Roth Capital dropped their Q4 2026 earnings estimates for shares of Core Scientific in a report released on Thursday, August 21st. Roth Capital analyst D. Aftahi now anticipates that the company will earn $0.01 per share for the quarter, down from their prior forecast of $0.03. Roth Capital has a "Neutral" rating and a $17.00 price target on the stock. The consensus estimate for Core Scientific's current full-year earnings is $0.52 per share. Roth Capital also issued estimates for Core Scientific's FY2027 earnings at $0.16 EPS and FY2028 earnings at $0.99 EPS.

Several other research analysts have also commented on the stock. Oppenheimer restated a "market perform" rating on shares of Core Scientific in a report on Monday, July 7th. Arete initiated coverage on shares of Core Scientific in a report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and issued a $17.00 price objective on shares of Core Scientific in a report on Friday, June 27th. Roth Mkm restated a "buy" rating and issued a $20.00 price objective on shares of Core Scientific in a report on Thursday, June 26th. Finally, Citigroup lowered shares of Core Scientific from an "outperform" rating to a "market perform" rating in a report on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Core Scientific currently has an average rating of "Hold" and a consensus target price of $18.32.

Core Scientific Price Performance

NASDAQ:CORZ remained flat at $14.35 during midday trading on Monday. 6,447,536 shares of the company were exchanged, compared to its average volume of 17,590,316. The business has a 50 day moving average of $14.19 and a two-hundred day moving average of $11.13. Core Scientific has a 52 week low of $6.20 and a 52 week high of $18.63. The firm has a market capitalization of $4.38 billion, a PE ratio of -25.63 and a beta of 6.60.

Core Scientific (NASDAQ:CORZ - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The firm had revenue of $78.63 million for the quarter, compared to the consensus estimate of $82.09 million. The company's quarterly revenue was down 44.3% on a year-over-year basis.

Institutional Trading of Core Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of CORZ. Driehaus Capital Management LLC grew its position in shares of Core Scientific by 112.1% in the 4th quarter. Driehaus Capital Management LLC now owns 10,264,204 shares of the company's stock worth $144,212,000 after buying an additional 5,424,901 shares during the period. Situational Awareness LP purchased a new stake in shares of Core Scientific in the 1st quarter worth about $32,736,000. Fred Alger Management LLC purchased a new stake in shares of Core Scientific in the 4th quarter worth about $62,011,000. Beryl Capital Management LLC grew its position in shares of Core Scientific by 24.3% in the 4th quarter. Beryl Capital Management LLC now owns 18,179,586 shares of the company's stock worth $255,423,000 after buying an additional 3,548,396 shares during the period. Finally, Clearline Capital LP grew its position in Core Scientific by 157.8% during the 1st quarter. Clearline Capital LP now owns 5,403,963 shares of the company's stock valued at $39,125,000 after purchasing an additional 3,308,100 shares during the last quarter.

Insider Buying and Selling at Core Scientific

In other news, insider Todd M. Duchene sold 7,759 shares of the company's stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $12.39, for a total value of $96,134.01. Following the sale, the insider directly owned 2,049,689 shares of the company's stock, valued at $25,395,646.71. This represents a 0.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 117,759 shares of company stock valued at $1,391,434. 1.40% of the stock is owned by corporate insiders.

Core Scientific Company Profile

Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.